Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated with a deleterious BRCA1 or BRCA2 mutation. Rucapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Mingxiang, Beltman, Jeri, Giordano, Heidi, Harding, Thomas C., Maloney, Lara, Simmons, Andrew D., Xiao, Jim J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652254/
https://www.ncbi.nlm.nih.gov/pubmed/36107395
http://dx.doi.org/10.1007/s40262-022-01157-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652254/
https://www.ncbi.nlm.nih.gov/pubmed/36107395
http://dx.doi.org/10.1007/s40262-022-01157-8

Ejemplares similares